Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron
Michelle Zhou, Marko Popovic, Mark Pasetka, Natalie Pulenzas, Soha Ahrari, Edward Chow, Carlo DeAngelis Department of Pharmacy, Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON, Canada Purpose: Nausea and vomiting are major adverse effects of che...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-05-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Online Access: | http://www.dovepress.com/update-on-the-management-of-chemotherapy-induced-nausea-and-vomiting-n-peer-reviewed-article-TCRM |
| _version_ | 1818694988366610432 |
|---|---|
| author | Zhou M Popovic M Pasetka M Pulenzas N Ahrari S Chow E DeAngelis C |
| author_facet | Zhou M Popovic M Pasetka M Pulenzas N Ahrari S Chow E DeAngelis C |
| author_sort | Zhou M |
| collection | DOAJ |
| description | Michelle Zhou, Marko Popovic, Mark Pasetka, Natalie Pulenzas, Soha Ahrari, Edward Chow, Carlo DeAngelis Department of Pharmacy, Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON, Canada Purpose: Nausea and vomiting are major adverse effects of chemotherapy and can greatly impact patients’ quality of life. Although chemotherapy-induced nausea and vomiting (CINV) prevalence is high, treatment remains difficult. Palonosetron is a 5-hydroxytryptamine receptor antagonist (5-HT3RA) approved for treatment of CINV. The purpose of this review is to discuss existing and emerging therapeutic options, and examine studies focusing on palonosetron with regards to efficacy, pharmacology, tolerability, safety, and patient-derived outcomes.Methods: A literature search was conducted using Ovid MEDLINE and EMBASE to identify relevant studies using palonosetron alone or in combination with other antiemetics. Studies were extracted if they included complete response (CR), complete control (CC), no nausea, no vomiting, and no rescue medications as an endpoint. Studies were also included if safety endpoints were examined.Results: Palonosetron alone has been shown to improve CR and CC rates for patients receiving low, moderate, or high emetogenic chemotherapy. Rates were further improved with the addition of dexamethasone, a corticosteroid. Furthermore, the addition of neurokinin-1 receptor antagonists, such as netupitant markedly improved efficacy profiles compared to palonosetron alone. Aprepitant is an antiemetic that has exhibited positive results in combination with palonosetron. Recently, a new drug consisting of netupitant and palonosetron (NEPA) has demonstrated significantly more efficacious prevention of CINV. Regardless of the combination, palonosetron has been well tolerated. The most common adverse events were constipation, headache, fatigue, and dizziness, with the majority of patients describing them as only mild or moderate.Conclusion: Palonosetron, alone or with other antiemetics, has improved CINV treatment due to its ability to significantly reduce delayed phases of CINV, compared to similar 5-HT3RAs. Palonosetron is both more effective than first generation 5-HT3RAs and safer, as it results in a smaller prolongation of the QTc interval, compared to other 5-HT3RAs. Keywords: chemotherapy-induced nausea and vomiting, palonosetron, efficacy, safety, pharmacology, patient-reported outcomes |
| first_indexed | 2024-12-17T13:38:19Z |
| format | Article |
| id | doaj.art-93fdb61061894431bd650ed0711d9e53 |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-12-17T13:38:19Z |
| publishDate | 2015-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-93fdb61061894431bd650ed0711d9e532022-12-21T21:46:23ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2015-05-012015default71372921601Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetronZhou MPopovic MPasetka MPulenzas NAhrari SChow EDeAngelis CMichelle Zhou, Marko Popovic, Mark Pasetka, Natalie Pulenzas, Soha Ahrari, Edward Chow, Carlo DeAngelis Department of Pharmacy, Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON, Canada Purpose: Nausea and vomiting are major adverse effects of chemotherapy and can greatly impact patients’ quality of life. Although chemotherapy-induced nausea and vomiting (CINV) prevalence is high, treatment remains difficult. Palonosetron is a 5-hydroxytryptamine receptor antagonist (5-HT3RA) approved for treatment of CINV. The purpose of this review is to discuss existing and emerging therapeutic options, and examine studies focusing on palonosetron with regards to efficacy, pharmacology, tolerability, safety, and patient-derived outcomes.Methods: A literature search was conducted using Ovid MEDLINE and EMBASE to identify relevant studies using palonosetron alone or in combination with other antiemetics. Studies were extracted if they included complete response (CR), complete control (CC), no nausea, no vomiting, and no rescue medications as an endpoint. Studies were also included if safety endpoints were examined.Results: Palonosetron alone has been shown to improve CR and CC rates for patients receiving low, moderate, or high emetogenic chemotherapy. Rates were further improved with the addition of dexamethasone, a corticosteroid. Furthermore, the addition of neurokinin-1 receptor antagonists, such as netupitant markedly improved efficacy profiles compared to palonosetron alone. Aprepitant is an antiemetic that has exhibited positive results in combination with palonosetron. Recently, a new drug consisting of netupitant and palonosetron (NEPA) has demonstrated significantly more efficacious prevention of CINV. Regardless of the combination, palonosetron has been well tolerated. The most common adverse events were constipation, headache, fatigue, and dizziness, with the majority of patients describing them as only mild or moderate.Conclusion: Palonosetron, alone or with other antiemetics, has improved CINV treatment due to its ability to significantly reduce delayed phases of CINV, compared to similar 5-HT3RAs. Palonosetron is both more effective than first generation 5-HT3RAs and safer, as it results in a smaller prolongation of the QTc interval, compared to other 5-HT3RAs. Keywords: chemotherapy-induced nausea and vomiting, palonosetron, efficacy, safety, pharmacology, patient-reported outcomeshttp://www.dovepress.com/update-on-the-management-of-chemotherapy-induced-nausea-and-vomiting-n-peer-reviewed-article-TCRM |
| spellingShingle | Zhou M Popovic M Pasetka M Pulenzas N Ahrari S Chow E DeAngelis C Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron Therapeutics and Clinical Risk Management |
| title | Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron |
| title_full | Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron |
| title_fullStr | Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron |
| title_full_unstemmed | Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron |
| title_short | Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron |
| title_sort | update on the management of chemotherapy induced nausea and vomiting ndash focus on palonosetron |
| url | http://www.dovepress.com/update-on-the-management-of-chemotherapy-induced-nausea-and-vomiting-n-peer-reviewed-article-TCRM |
| work_keys_str_mv | AT zhoum updateonthemanagementofchemotherapyinducednauseaandvomitingndashfocusonpalonosetron AT popovicm updateonthemanagementofchemotherapyinducednauseaandvomitingndashfocusonpalonosetron AT pasetkam updateonthemanagementofchemotherapyinducednauseaandvomitingndashfocusonpalonosetron AT pulenzasn updateonthemanagementofchemotherapyinducednauseaandvomitingndashfocusonpalonosetron AT ahraris updateonthemanagementofchemotherapyinducednauseaandvomitingndashfocusonpalonosetron AT chowe updateonthemanagementofchemotherapyinducednauseaandvomitingndashfocusonpalonosetron AT deangelisc updateonthemanagementofchemotherapyinducednauseaandvomitingndashfocusonpalonosetron |